BioCardia Jumps After FDA Feedback Seen Positive for CardiAMP Approval
BioCardia shares soared 52% to $1.40 after FDA meeting minutes confirmed its CardiAMP HF II trial may support a PMA for heart-failure cell therapy, bucking a weak biotech sector; the move highlights investor focus on regulatory progress, though risks remain with cash needs and Nasdaq compliance.